Aasha I Hoogland1, Hailey W Bulls1, Brian D Gonzalez1, Brent J Small2, Lianqi Liu3, Joseph Pidala4, Heather S L Jim1, Asmita Mishra5. 1. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA. 2. School of Aging Studies, University of South Florida, Tampa, Florida, USA. 3. Department of Psychiatry, University of California, San Diego, La Jolla, California, USA. 4. Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. 5. Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. Electronic address: asmita.mishra@moffitt.org.
Abstract
CONTEXT: Quality of life (QoL) is increasingly recognized as an important outcome of cancer treatment. Previous studies have examined clinical predictors of QoL, but with the increasing prevalence of wearable sensors that monitor sleep and activity patterns, further investigation into whether these behaviors are predictive of post-treatment QoL is now feasible. Among patients receiving aggressive cancer treatment such as hematopoietic cell transplantation (HCT), analysis of circadian rhythms (24-hour patterns of sleep and activity) via wearable sensors is limited. OBJECTIVE: To evaluate the relationship between overall QoL and circadian rhythms in patients receiving allogeneic HCT. METHODS: Patients wore an ActiGraph GT3X (Pensacola, FL) activity monitor for at least 72 hours before the initiation of conditioning chemotherapy and transplantation and completed a QoL (Functional Assessment of Cancer Therapy-General [FACT-G]) assessment. QoL assessments were also completed 1, 3, and 6 months after HCT. RESULTS: Patients (n = 45, M age = 55) were mostly male (66%) with a total FACT-G score of 80.96 (SD = 16.05) before HCT. Mixed models revealed robust cross-sectional associations between overall QoL and multiple circadian rhythmicity parameters, including durations of high physical activity, overall circadian rhythmicity, and earlier starts of daily activity (P's < .01). Recovery of QoL after transplant was predicted by longer pre-transplant durations of high physical activity (P = .04) and earlier evening retirement (P = .04). CONCLUSION: Our findings suggest that wearable sensor information is a promising method of predicting recovery of QoL after HCT. Additional studies are needed to confirm these findings in a larger sample.
CONTEXT: Quality of life (QoL) is increasingly recognized as an important outcome of cancer treatment. Previous studies have examined clinical predictors of QoL, but with the increasing prevalence of wearable sensors that monitor sleep and activity patterns, further investigation into whether these behaviors are predictive of post-treatment QoL is now feasible. Among patients receiving aggressive cancer treatment such as hematopoietic cell transplantation (HCT), analysis of circadian rhythms (24-hour patterns of sleep and activity) via wearable sensors is limited. OBJECTIVE: To evaluate the relationship between overall QoL and circadian rhythms in patients receiving allogeneic HCT. METHODS:Patients wore an ActiGraph GT3X (Pensacola, FL) activity monitor for at least 72 hours before the initiation of conditioning chemotherapy and transplantation and completed a QoL (Functional Assessment of Cancer Therapy-General [FACT-G]) assessment. QoL assessments were also completed 1, 3, and 6 months after HCT. RESULTS:Patients (n = 45, M age = 55) were mostly male (66%) with a total FACT-G score of 80.96 (SD = 16.05) before HCT. Mixed models revealed robust cross-sectional associations between overall QoL and multiple circadian rhythmicity parameters, including durations of high physical activity, overall circadian rhythmicity, and earlier starts of daily activity (P's < .01). Recovery of QoL after transplant was predicted by longer pre-transplant durations of high physical activity (P = .04) and earlier evening retirement (P = .04). CONCLUSION: Our findings suggest that wearable sensor information is a promising method of predicting recovery of QoL after HCT. Additional studies are needed to confirm these findings in a larger sample.
Authors: Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer Journal: Blood Date: 2005-06-30 Impact factor: 22.113
Authors: Sonia Ancoli-Israel; Lianqi Liu; Matthew R Marler; Barbara A Parker; Vicky Jones; Georgia Robins Sadler; Joel Dimsdale; Mairav Cohen-Zion; Lavinia Fiorentino Journal: Support Care Cancer Date: 2005-07-12 Impact factor: 3.603
Authors: M C Mormont; J Waterhouse; P Bleuzen; S Giacchetti; A Jami; A Bogdan; J Lellouch; J L Misset; Y Touitou; F Lévi Journal: Clin Cancer Res Date: 2000-08 Impact factor: 12.531
Authors: Tyvin Rich; Pasquale F Innominato; Julie Boerner; M Christine Mormont; Stefano Iacobelli; Benoit Baron; Claude Jasmin; Francis Lévi Journal: Clin Cancer Res Date: 2005-03-01 Impact factor: 12.531
Authors: Michael Littner; Clete A Kushida; W McDowell Anderson; Dennis Bailey; Richard B Berry; David G Davila; Max Hirshkowitz; Sheldon Kapen; Milton Kramer; Daniel Loube; Merrill Wise; Stephen F Johnson Journal: Sleep Date: 2003-05-01 Impact factor: 5.849
Authors: Sonia Ancoli-Israel; Roger Cole; Cathy Alessi; Mark Chambers; William Moorcroft; Charles P Pollak Journal: Sleep Date: 2003-05-01 Impact factor: 5.849
Authors: Jennifer M Knight; Mallory R Taylor; Kelly E Rentscher; Elisabeth C Henley; Hannah A Uttley; Ashley M Nelson; Lucie M Turcotte; Natalie S McAndrew; Hermioni L Amonoo; Lathika Mohanraj; Debra Lynch Kelly; Erin S Costanzo Journal: Front Immunol Date: 2022-07-05 Impact factor: 8.786